NASDAQ:JBIO - Nasdaq - US0080641071 - Common Stock - Currency: USD
9.89
+0.48 (+5.1%)
The current stock price of JBIO is 9.89 USD. In the past month the price increased by 32.04%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.04 | 327.31B | ||
AMGN | AMGEN INC | 13.94 | 155.58B | ||
GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
NTRA | NATERA INC | N/A | 23.47B | ||
INSM | INSMED INC | N/A | 18.70B | ||
BIIB | BIOGEN INC | 8.03 | 18.62B |
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2021-06-30. The firm is in the process of exploring strategic alternatives, which may include, but are not limited to, an acquisition, merger, reverse merger, business combination, liquidation or other transaction.
JADE BIOSCIENCES INC
930 Winter Street, Suite M-500
Waltham MASSACHUSETTS US
Employees: 4
Phone: 16174432400
The current stock price of JBIO is 9.89 USD. The price increased by 5.1% in the last trading session.
The exchange symbol of JADE BIOSCIENCES INC is JBIO and it is listed on the Nasdaq exchange.
JBIO stock is listed on the Nasdaq exchange.
11 analysts have analysed JBIO and the average price target is 18.36 USD. This implies a price increase of 85.64% is expected in the next year compared to the current price of 9.89. Check the JADE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
JADE BIOSCIENCES INC (JBIO) has a market capitalization of 318.85M USD. This makes JBIO a Small Cap stock.
JADE BIOSCIENCES INC (JBIO) currently has 4 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
JADE BIOSCIENCES INC (JBIO) has a dividend yield of 849.34%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of JBIO dividend history, reliability and sustainability.
JADE BIOSCIENCES INC (JBIO) will report earnings on 2025-08-11, after the market close.
JADE BIOSCIENCES INC (JBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-59.5).
The outstanding short interest for JADE BIOSCIENCES INC (JBIO) is 0.74% of its float. Check the ownership tab for more information on the JBIO short interest.
ChartMill assigns a technical rating of 4 / 10 to JBIO.
ChartMill assigns a fundamental rating of 3 / 10 to JBIO. JBIO has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months JBIO reported a non-GAAP Earnings per Share(EPS) of -59.5. The EPS increased by 44.08% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -63.15% | ||
ROE | -65.24% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to JBIO. The Buy consensus is the average rating of analysts ratings from 11 analysts.